指南与共识

德国精准肿瘤医学概念框架:德国癌症援助工作组「分子诊断与治疗」共识声明

Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'.
指南 / 共识 · Eur J Cancer · 2020-06-07

德国癌症援助(DKH)支持的工作组「分子诊断与治疗」通过两场研讨会及改良德尔菲法(在线问卷)制定共识,由十四家综合癌症中心代表参与,起草并评估了九项声明,旨在为德国精准肿瘤医学(PCM)的未来实施提供质量导向、协调且可适应的协作策略基础。

要点

  • 十四家综合癌症中心代表参与制定九项共识声明。
  • 采用改良德尔菲法与在线问卷评估声明。
  • 共识旨在指导德国精准肿瘤医学的质量导向实施。

核心结论

  • 九项共识声明可作为德国精准肿瘤医学未来协作策略的基础,以维持并进一步提升其质量。

研究设计与样本

  • 由德国癌症援助(DKH)支持的工作组「分子诊断与治疗」实施,十四家综合癌症中心代表参与两场研讨会,基于在线问卷采用改良德尔菲法起草并评估九项声明。

主要发现

  • 工作组识别了实施质量导向、协调且可适应的精准肿瘤医学所需的关键主题。
  • 九项声明在工作组内起草并完成评估。

临床怎么用

  • 共识声明可为德国精准肿瘤医学的进一步发展和广泛采用提供协作策略框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precision cancer medicine (PCM) holds great promises to offer more effective therapies to patients based on molecular profiling of their individual tumours. Although the PCM approach seems intuitive, multiple conceptional and structural challenges interfere with the broad implementation of PCM into clinical practice. Accordingly, concerted national and international efforts are needed to guide the further development and broad adoption of PCM in Germany. With support of the 'German Cancer Aid' (Deutsche Krebshilfe [DKH]) a task force 'Molecular Diagnostics and Therapy' was implemented. In two workshops supported by the DKH, delegates from the fourteen comprehensive cancer centresidentified key topics essential to implement quality-guided, harmonized and adaptable PCM. Based on an online questionnaire and using a modified Delphi approach, nine statements were drafted and evaluated within the group. These statements could serve as a basis to define a collaborative strategy for PCM in the future with the aim to sustain and further improve its quality.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Westphalen BC, Bokemeyer C, Büttner R, et al. Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. Eur J Cancer. 2020. PMID: 32521293. doi:10.1016/j.ejca.2020.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。